

Table of Contents

| | |
|--|----|
| Prologue | 6 |
| 1 Introduction | 11 |
| 2 Definitions and surgical technical overview | 15 |
| 2.1 Minimally Invasive Glaucoma Surgery (MIGS) | 15 |
| 2.1.1 Trabecular procedures and devices | 16 |
| 2.1.2 Suprachoroidal devices | 17 |
| 2.2 Bleb-forming devices | 18 |
| 3 Literature review and recommendations | 21 |
| 3.1 Methodology | 21 |
| 3.1.1 Identification of key clinical questions | 21 |
| 3.1.2 Summarizing available evidence | 21 |
| 3.1.3 Study selection | 22 |
| 3.1.4 Data synthesis | 22 |
| 3.2 Summary of current evidence and clinical interpretation | 23 |
| 3.2.1 Trabecular stenting devices | 23 |
| 3.2.2 Trabecular procedures | 26 |
| 3.2.3 Suprachoroidal devices | 27 |
| 3.2.4 Bleb-forming devices | 28 |
| 3.2.5 Results from comparison studies and Consensus notes | 29 |
| 3.2.6 Phacoemulsification | 34 |
| 3.3 Clinical recommendations | 34 |
| 3.4 Key questions | 35 |
| 3.5 Cost-effectiveness of innovative surgery | 42 |
| 4 Recommendations for surgical innovation in glaucoma | 45 |
| 4.1 IDEAL phases | 46 |
| 4.2 Training | 48 |
| 4.3 Safety and consent | 48 |
| 4.4 Clinical governance | 48 |
| 4.5 Conflicts of interest | 49 |
| 4.6 Summary | 50 |

| | |
|--|----|
| 5 Overview of study designs | 53 |
| 5.1 Randomized controlled trials in glaucoma | 53 |
| 5.1.1 Randomized controlled trials evaluating surgical innovations | 54 |
| 5.1.2 'Real world data' and the value of EPRs | 55 |
| 6 How to present data from glaucoma surgical trials | 61 |
| 6.1 Intraocular pressure | 61 |
| 6.1.1 Tonometry | 61 |
| 6.1.2 Defining baseline IOP | 62 |
| 6.1.3 Target IOP | 62 |
| 6.1.4 Success as an outcome parameter | 62 |
| 6.1.5 Failed IOP control, visual loss, and further surgery | 63 |
| 6.2 Visual acuity | 63 |
| 6.3 Visual field parameters | 64 |
| 6.4 Structural outcomes | 64 |
| 6.5 Quality of life | 64 |
| 6.6 Overall data presentation | 64 |
| 6.6.1 Mean or median IOP values | 65 |
| 6.6.2 Kaplan-Meier curve | 66 |
| 6.6.3 Scatterplot | 66 |
| 6.6.4 Preoperative versus postoperative medication | 67 |
| 6.6.5 Graphical representation of visual acuity | 68 |
| 6.7 Methods of analysis and reporting | 69 |
| 6.7.1 Descriptive statistics | 69 |
| 6.7.2 Minimal clinically important difference (MCID) | 69 |
| 6.7.3 Kaplan-Meier curves | 70 |
| 6.7.4 Missing data | 71 |
| 6.7.5 Standards for reporting | 71 |
| 7 Complications | 73 |
| 7.1 Definition of complications | 73 |
| 7.2 Severity grading | 74 |
| 7.3 Timing of harm reporting | 74 |
| 7.4 Reporting complications | 75 |

| | |
|---|-----|
| 8 Outcomes for clinical trials | 87 |
| 8.1 The problem of outcome multiplicity | 87 |
| 8.2 What are core outcome sets? | 87 |
| 8.3 Core outcome set development | 88 |
| 8.3.1 Stakeholder involvement | 88 |
| 8.3.2 Steps of core outcome set development | 88 |
| 8.3.3 COMET database and core outcome sets in Ophthalmology | 88 |
| 8.3.4 Advantages of core outcome sets | 89 |
| 8.3.5 Summary | 89 |
| 8.4 Outcomes and descriptors for glaucoma studies evaluating surgical innovations | 89 |
| 8.4.1 Methodology | 90 |
| 8.4.2 Descriptors | 96 |
| 8.4.3 Outcomes | 98 |
| Epilogue | 105 |
| References | 110 |